HYLATOPICPLUS LOTION Rx
Generic Name and Formulations:
Water, glycerin, ethylhexyl palmitate, propylene glycol, cetearyl alcohol, theobroma grandiflorum seed butter, dicetyl phosphate, dimethicone, petrolatum, tocopheryl acetate, steareth-10, phenoxyethanol, ceteareth-10 phosphate, hydroxypropyl bispalmitamide MEA (ceramide), disodium EDTA, sodium hyaluronate and sodium hydroxide; lotion.
Encore Dermatology, Inc.
Indications for HYLATOPICPLUS LOTION:
Dermatitis (including radiation dermatitis). Dry skin.
Adults and Children:
Apply and massage into affected area 3 times daily or as needed. Broken skin: may be occluded.
Avoid eyes and exposure to sun. Treatment may be continued during antiinfective therapy. Reevaluate if no improvement after 10–14 days.
Radiation therapy: may dissolve fuchsin dye; do not use 4 hours prior to session.
Foam—100g, 150g; Crm—100g, 450g, Lotion—14oz
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies